Results 131 to 140 of about 323,772 (303)
Clinical Pharmacology &Therapeutics, EarlyView.Real‐world evidence (RWE) derived from real‐world data (RWD) can complement randomized controlled trials (RCTs), yet the validity of RWD relative to RCT data remains insufficiently characterized. We obtained post hoc consent and linked individual participant data from the US‐based INVESTED trial (2016–2019) with Medicare fee‐for‐service claims (2012 ...
Hanseul Cho +12 more
wiley +1 more source
Advancing Regulatory Adoption of New Approach Methodologies
Clinical Pharmacology &Therapeutics, EarlyView.The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has a long history advancing new approach methodologies (NAMs). In collaboration with external organizations and other regulatory agencies, FDA supports continued development of NAMs for regulatory use.
Jeffry Florian +7 more
wiley +1 more source
Role of selenium in the pathophysiology of cardiorenal anaemia syndrome
ESC Heart Failure, Volume 12, Issue 2, Page 770-780, April 2025.Abstract Chronic kidney disease (CKD) and cardiovascular disease (CVD) have multiple bidirectional mechanisms, and anaemia is one of the critical factors that are associated with the progression of the two disorders [referred to as cardiorenal anaemia syndrome (CRAS)].
Shigeyuki Arai +2 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi +4 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 888-899, April 2025.Abstract Aims Heart failure with preserved ejection fraction (HFpEF) continues to be an increasingly common health problem associated with a high mortality rate. Elevated levels of Growth differentiation factor‐15 (GDF15) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) are reportedly associated with poor clinical outcomes in a broad range of ...
Yoichiro Otaki +11 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1194-1202, April 2025.Abstract Aims Cardiac decompensation in cardiorenal syndrome (CRS) results in systemic congestion usually treated with diuretics. When despite high doses of diuretics, response is poor, ultrafiltration (UF) appears to be a useful and safe technique.
Borja Guerrero Cervera +12 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou +3 more
wiley +1 more source